57th ASH Annual Meeting and Exposition (December 5-8, 2015): 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster III

Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents Oral and Poster Abstracts
Poster

Hall A, Level 2 (Orange County Convention Center)

Development of Masitinib for the Treatment of Peripheral T-Cell Lymphoma

Olivier Hermine¹^*, Ambroise Marçais, MD²^*, Thiago Maciel³^*, J Bagbor²^*, Darius Jagielski, VMD⁴^*, Nadine Holtermann, VMD⁵^*, Elena Martinez de Merlo, VMD⁶^*, Douglas H. Thamm, VMD⁷^*, Patrice Dubreuil, PhD⁸^* and Alain Moussy, MBA⁸^*

¹Department of Hematology, Necker Children's hospital, APHP, Paris, France
²Service d’hématologie and Imagine Institute, Necker Hospital, Paris, France
³Service d’hématologie and Imagine Institute, Necker Hospital, paris, France
⁴Bialobrzeska Veterinary Clinic, Warsaw, Poland
⁵Medizinische Kleintierklinik, Universität München, Munich, Germany
⁶Dept. of Animal Medicine and Surgery, HCVC, Complutense University of Madrid, Madrid, Spain
⁷The Animal Cancer Center, Colorado State University, Fort Collins, CO
⁸AB Science, Paris, France

3994

Pevonedistat Sensitizes Diffuse Large B-Cell Lymphoma Cells to Death Receptor Ligand-Mediated Apoptosis

Cody Paiva, BS¹^*, Claire Godbersen²^*, Christopher George Danes, PhD,³^*, Stephen E Spurgeon, MD⁴, Allison Berger³^* and Alexey V Danilov, M.D. Ph.D.¹

¹OHSU Knight Cancer Institute, Portland, OR
²Dartmouth College, Lebanon, NH
³Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd., Cambridge, MA
⁴Center for Hematologic Malignancies, Oregon Health & Science University, Portland, OR

3995

BARs (B-cell receptor antigens for reverse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms

Michael Pfreundschuh, MD¹, Lorenz Thurner, MD¹^*, Stefan Barth, Prof.Dr.²^*, Diana Pickert³^*, Natalie Fadle¹^*, Maria Kemele¹^*, Evi Regitz¹^*, Frank Neumann, PhD⁴^*, Thomas Nachreiner, Dr.³^* and Klaus-Dieter Preuss, PhD¹^*

¹José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany
²Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, South African Research Chair in Cancer Biotechnology Institute of Infectious Disease and Molecular Medicine (IDM) Department of Integrative Biomedical Science Faculty of Health Sciences, Cape Town, South Africa
³Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, University Hospital RWTH Aachen, Aachen, Germany
⁴José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg, Germany

3996

The xCT Antiporter Is a Therapeutic Target in the ABC Subtype of DLBCL

Xiaolei Wei, Dr.¹^*, Yun Mai, Dr.¹^*, Ru Feng, MD² and B. Hilda Ye, PhD¹

¹Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY
²Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China

3997

Palbociclib (PD-0332991), a Potent Selective CDK4/6 Inhibitor, Overcomes Therapy-Resistant and Sensitizes Diffuse Large B-Cell Lymphoma Pre-Clinical Models to Chemo-Reagents

Juan J Gu, PhD¹^*, Qunling Zhang, MD, PhD^1,2^*, Cory Mavis, MSc¹^*, Myron S. Czuczman, MD^1,3 and Francisco J. Hernandez-Ilizaliturri, MD¹

¹Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, NY
²Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
³Celgene Corporation, Summit, NJ

3998

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

Patrick P. Ng, Daniel K. Lu^*, Juthamas Sukbuntherng^*, Jutta K. Neuenburg, Danelle F. James^* and Betty Y. Chang, PhD

Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA

3999

SFRP4-Mediated Inhibition of Canonical Wnt-Signaling in DLBCL

Raphael Koch, MD¹^* and Bjoern Chapuy, MD, PhD²

¹Hematology & Oncology, University Medical Center Goettingen, Goettingen, Germany
²Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

4000

Potent Preclinical Activity of Ponatinib in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (GCB-DLBCL) Models

Joseph M. Gozgit^*, Youngchul Song^*, Scott Wardwell^*, Sara Nadworny^*, Yaoyu Ning^* and Victor M. Rivera

ARIAD Pharmaceuticals, Inc., Cambridge, MA

4001

B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development

Amanda L Christie, B.S.¹^*, Alexandra N. Christodoulou, M.S.¹^*, Tiffany DeSouza, B.S.¹^*, Mark A. Murakami, MD, MA¹, Loretta S. Li, MD², Nadja Kopp, M.S.²^*, Raphael Koch, MD²^*, Abner Louissaint Jr., MD, PhD³, Samuel Y. Ng, MD, PhD², Caron A. Jacobson, MD³, Brent Shoji, MD⁴^*, Matthew S. Davids, MD³, Oreofe O. Odejide, MD³, Ann S. LaCasce, MD³, David C. Fisher, MD², Arnold S. Freedman, MD², Eric D. Jacobsen, MD², Monica Bertagnolli, MD⁴^*, Geraldine S Pinkus, MD⁵^*, David M. Dorfman, MD, PhD⁶, Elizabeth A. Morgan, MD⁶, Jon C Aster, MD PhD⁵, Margaret A. Shipp, MD³ and David M. Weinstock²

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
³Dana-Farber Cancer Institute, Boston, MA
⁴Department of Surgery, Brigham and Women's Hospital, Boston, MA
⁵Pathology, Brigham and Women's Hospital, Boston, MA
⁶Department of Pathology, Brigham and Women's Hospital, Boston, MA

4002

Natural Toll-like Receptor Agonists for in Situ Vaccination Lymphoma Immunotherapy

Paul Peng, PhD¹, Joshua Brody, MD² and Linda Hammerich, PhD¹^*

¹Icahn School of Medicine at Mount Sinai, New York, NY
²Ichan School of Medicine at Mount Sinai, New York, NY

4003

Preclinical Evaluation of the Oral Proteasome Inhibitor Ixazomib in Diffuse Large B-Cell Lymphoma

Wei Liu, MD¹^*, Archie Tamayo, MS²^*, Juan Chen, Ph.D²^*, Shimin Hu, PhD, MD³^*, Richard J. Ford Jr., MD, PhD⁴ and Lan Pham, PhD⁵

¹Department of Pathology, Soochow University, Suzhou, Jiangsu, China
²Department of Hematopathology, UT MD Anderson Cancer Center, Houston, TX
³University of Texas MD Anderson Cancer Center PTH Program, Houston, TX
⁴Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
⁵Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

4004

Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia

Guang Yang, PhD¹, Xia Liu, MD¹^*, Jie Chen, PhD¹^*, Lian Xu¹^*, Nicholas Tsakmaklis¹^*, Jiaji Chen¹^*, Christopher J Patterson, MFA¹^*, Jorge J Castillo, MD¹, Philip Cohen²^*, Li Tan, PhD³^*, Sara Buhrlage, PhD³^*, Nathanael Gray, PhD³^* and Steven P Treon, MD, PhD¹

¹Bing Center for WM, Dana Farber Cancer Institute, Boston, MA
²2MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dundee, United Kingdom
³Dept of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA

4005

The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas

Chiara Tarantelli¹^*, Eugenio Gaudio¹^*, Ivo Kwee¹^*, Luciano Cascione¹^*, Elena Bernasconi¹^*, Petra Hillmann²^*, Anastasios Stathis, MD³^*, Georg Stussi, MD⁴, Doriano Fabbro²^*, Andreas Wicki⁵^*, Emanuele Zucca⁴, Vladimir Cmiljanovic²^* and Francesco Bertoni¹

¹Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland
²PIQUR Therapeutics AG, Basel, Switzerland
³Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
⁴IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
⁵University of Basel, Basel, Switzerland

4006

Dual Inhibition of PKC Delta By Carfilzomib (CFZ) and Ibrutinib Results in Synergistic Activity in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Pre-Clinical Models and in Primary Tumor Cells Isolated from B-Cell Lymphoma Patients

Qunling Zhang, MD, PhD^1,2^*, Juan J Gu, PhD¹^*, Ye Guo, MD²^*, Jacob Klos¹^*, Cory Mavis, MSc¹^*, Myron S. Czuczman, MD^1,3 and Francisco J. Hernandez-Ilizaliturri, MD¹

4007

CC-122 Exhibits Potent Anti-Lymphoma Activity in Combination with Obinutuzumab through Cell Autonomous and Antibody Dependent Cell Mediated Cytotoxicity

Hsiling Chiu¹^*, Patrick Hagner, PhD¹^*, Michael Pourdehnad, MD²^*, Thomas Daniel³^*, Rajesh Chopra¹, Anke Klippel¹, Christian Klein, PhD⁴, Anjan Thakurta¹^* and Anita K. Gandhi, PhD¹^*

¹Celgene Corporation, Summit, NJ
²Celgene Corporation, San Francisco, CA
³Celgene Corporation, San Diego, CA
⁴Roche Pharmaceutical Research and Early Development Roche Innovation Center, Zurich, Switzerland

4008

Metformin Induces p53-Dependent Mitochondrial Stress in Therapy-Sensitive and -Resistant Lymphoma Pre-Clinical Model and Primary Patients Sample with B-Cell Non-Hodgkin Lymphoma (NHL)

Juan J Gu, PhD¹^*, Qunling Zhang, MD, PhD^1,2^*, Cory Mavis, MSc¹^*, Myron S. Czuczman, MD^1,3 and Francisco J. Hernandez-Ilizaliturri, MD¹

4009

ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies

Niranjan S. Rao, PhD¹^*, Sanjeeva Reddy, PhD¹^*, Gupta Sandeep, PhD¹^*, Nitin K Damle, PhD²^*, Venkatesan M Aranapakam, PhD³^*, Scott Thompson, PhD¹^*, Roger Smith, PhD¹^*, Terry Plasse, MD⁴^*, Penelope Bristow, MS¹^*, Anthony Tolcher, MD⁵^*, Kyriakos P Papadopoulos, MD⁵, Amita Patnaik, MD⁵^* and Drew W Rasco, MD⁵^*

¹Asana BioSciences, LLC, Bridgewater, NJ
²Preclinical R&D, Sun Pharma Advanced Research Co. Ltd.,, Mumbai 400093, India, Mumbai, India
³Axcellerate Pharma LLC, , NJ 08854, Piscataway, NJ
⁴Plasse Pharma, New York, NY
⁵START, San Antonio, TX

4010

Development of an Anti-HTLV-1 Vaccine for the Treatment of Adult T-Cell Leukemia/Lymphoma

Déborah Revaud, PhD¹^*, Ana Bejanariu, PhD²^*, Lamya Loussaief¹^*, Emeline Sarry²^*, Abdel Zemmar²^*, Guillaume Deplaine, PhD¹^*, Téreza Coman, MD^3,4,5,6^*, Julien Rossignol, MD^3,4,5,6^*, Olivier Hermine^3,4,5,7^* and Cecile Bauche, PhD²^*

¹THERAVECTYS, Villejuif, France
²THERAVECTYS, VILLEJUIF, France
³Department of Hematology, Necker Children's hospital, APHP, Paris, France
⁴Imagine Institute, Sorbonne Paris Cité, Paris Descartes University, Paris, France
⁵Centre de référence des déficits immunitaires héréditaires (CEREDIH), Necker Children's hospital, APHP, Paris, France
⁶Imagine Institute, INSERM UMR 1163, CNRS ERL 8654, Paris, France
⁷Institut Imagine, INSERM 1163/CNRS ERL 8254, Paris, France

4011

ONC201 Induces Apoptosis in Cutaneous T-Cell Lymphoma Cells through a Mechanism That Involves the Integrated Stress Response and Inactivation of Jak/Stat Signaling

Madeleine Duvic, MD¹, Xiang Zhang²^*, Xiao Ni, MD, PhD¹, Timothy Langridge³^*, Rohinton Tarapore, Ph.D.⁴^* and Josh Allen, PhD⁵^*

¹Dept. of Dermatology, M.D. Anderson Cancer Center, Houston, TX
²Department of Dermatology, Univ of Texas MD Anderson Cancer Ctr, Houston, TX
³Dermatology, Univ of Texas MD Anderson Cancer Center, Houston, TX
⁴Oncoceutics, Inc, Hummelstown, PA
⁵Oncoceutics, Hummelstown, PA

See more of: Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH